Virtual platform aims to cut HIV comorbidities

NCT ID NCT06580184

Not yet recruiting Prevention Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a virtual platform called LEARN 2 that provides tailored education to help men living with HIV prevent related health problems like heart disease and metabolic issues. Participants will use the platform weekly, attend live health educator sessions, and track their daily behaviors. Researchers will compare their quality of life and risk factors to a waitlist group to see if the program makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LEARN 2 Platform (behavioral intervention)
What this could lead to: If it works, this could provide an effective way to reduce the risk of serious health problems like heart disease in people living with HIV.
What could go wrong: This is a small, early-stage trial with no drug involved, so any benefits may be modest. The results may not apply to all people with HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CVD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus HIV infectious disease metabolic disease neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CVD HIV METABOLIC DISEASE

Contacts and locations

Locations

Yale University

Orange, Connecticut, 06477, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.